Ben Kingsley reunites with Ahmed Salim for 'Whispers of Wisdom' in Uzbekistan

“Working with Sir Ben Kingsley again is a huge honour. Our earlier collaboration showed the extraordinary power of film to engage global audiences with stories of science, culture and shared heritage. With Whispers of Wisdom, we are creating a new generation of cinematic stories centred on the remarkable scholars of Uzbekistan and the region.” — Ahmed Salim, Executive Producer of 'Whispers of Wisdom'

Academy Award-winning actor Sir Ben Kingsley has completed filming Whispers of Wisdom, a new film series produced in UK and Uzbekistan. The series reunites Kingsley with award-winning Executive Producer Ahmed Salim (1001 Inventions), and explores the lives, ideas and enduring legacy of pioneering scholars from Uzbekistan and the broader region whose work helped shape fields such as mathematics, astronomy, medicine and engineering.

LONDON / TASHKENT - Academy Award-winning actor Sir Ben Kingsley has completed filming Whispers of Wisdom, a new film series with Executive Producer Ahmed Salim (1001 Foundation) telling the stories of pioneering scholars from Uzbekistan and the broader region. The series has been created for the Centre for Islamic Civilization in Uzbekistan as part of a wider media initiative designed for museum visitors and international audiences.

Created as cinematic portraits, Whispers of Wisdom explores the lives, discoveries and continuing relevance of scholars whose ideas helped shape fields such as mathematics, algorithms, astronomy, medicine, physics, engineering and geography. The wider 1001 Inventions Uzbekistan initiative highlights figures such as Al-Khwarizmi, Al-Biruni, Ibn Sina and Ulugh Beg, helping audiences connect the region’s intellectual legacy with the modern world.

The project is part of a major international production bringing together Uzbek and international filmmakers. The production includes Spectre Films (UZ), Director Shokhrukh Rasulov, Producer Gayrat Muminov, Director of Photography Max Tsui, and award-winning Executive Producer Ahmed Salim, founder of 1001 Foundation.

For Ahmed Salim, the project marks a special reunion with Sir Ben Kingsley following their earlier collaboration on the acclaimed short film 1001 Inventions and the Library of Secrets, produced as part of the global 1001 Inventions initiative. That film helped introduce a richer understanding of the history of science and received more than twenty international awards and seen by more than 200 million people.

Ahmed Salim is an award-winning producer known for developing ambitious cultural and educational media projects that combine film, exhibitions and public engagement. Among his most notable productions was 1001 Inventions and the World of Ibn Al-Haytham, which he produced and co-directed and which starred Omar Sharif in what became the legendary actor’s final film appearance before his death.

The involvement of 1001 Foundation in Whispers of Wisdom reflects its long-standing mission to transform stories from the history of science and civilisation into powerful, accessible experiences for audiences around the world. Through award-winning films, exhibitions, books and educational campaigns, 1001 Foundation has spent many years helping audiences rediscover the contributions of scholars, thinkers and innovators whose impact still shapes our world today.

In Uzbekistan, this work extends beyond film. 1001 Foundation has also been involved in developing the children’s interactive exhibition 1001 Inventions from Uzbekistan to the World at the Centre for Islamic Civilization of Uzbekistan. That exhibition invites children and families into a hands-on STEM journey through the First and Second Renaissances of Central Asia, using cinematic storytelling, games, immersive sets and digital installations to bring historical pioneers to life.

Together, the Whispers of Wisdom film series and the children’s exhibition represent an important new chapter in the Centre’s public engagement work, combining scholarship, creativity and world-class production to present Uzbekistan’s intellectual heritage in fresh and inspiring ways. As Whispers of Wisdom moves closer to launch, the project stands as another example of how meaningful collaboration between filmmakers, cultural institutions and educational producers can bring the stories of the past to life for new generations.

Video Link: https://www.youtube.com/embed/Dj5LPzpS00A

Media Contact
Company Name: 1001 Foundation
Contact Person: Media Office
Email:Send Email
City: London
Country: United Kingdom
Website: 1001.org

Wilson’s Disease Market to Reach New Heights by 2034 with Advancing Gene Therapies and Strong Pipeline from Vivet Therapeutics, Pfizer, and Ultragenyx Pharmaceutical | DelveInsight

Wilson’s Disease Market

Leading Wilson’s Disease companies, including Orphalan, AstraZeneca, Vivet Therapeutics, Pfizer,Ultragenyx Pharmaceutical, and others, are developing novel products to improve the Wilson's Disease treatment outlook.

DelveInsight’s “Wilson’s Disease Market Insights, Epidemiology, and Market Forecast – 2034” report provides an extensive analysis of Wilson’s Disease across the United States, EU4, the United Kingdom, and Japan. It covers historical and future epidemiology, current and emerging treatment trends, and market dynamics. The report also examines market size and share, key growth drivers and challenges, late-stage pipeline therapies, clinical trial developments, and major company activities influencing market expansion and therapy uptake in Wilson’s Disease.

 

According to DelveInsight, around 8,000 diagnosed prevalent cases of Wilson’s Disease were reported across the 7MM in 2023, with numbers projected to rise steadily through 2034. The United States accounted for the largest market share, reaching approximately USD 126 million in 2023 and expected to grow at a CAGR of about 13% during the forecast period.

Current treatment approaches primarily include chelating agents such as D-penicillamine and trientine, along with zinc-based therapies. Among these, chelating agents dominated the U.S. market, contributing nearly USD 123 million in 2023. A notable regulatory milestone was the 2022 approval of CUVRIOR by the U.S. Food and Drug Administration for adults with stable disease who are tolerant to penicillamine.

Market growth is being driven by improved disease awareness, advancements in genetic diagnostics, and increasing focus on rare disease research. Additional support comes from patient advocacy efforts and rising healthcare investments.

Recent developments further highlight innovation in this space. In 2026, Hyloris Pharmaceuticals secured European and Turkish rights for a next-generation therapy, with clinical trials expected to begin soon. In 2025, Monopar Therapeutics reported encouraging Phase II data demonstrating effective copper reduction. Additionally, updated clinical guidelines were released by European Association for the Study of the Liver and European Reference Network, improving diagnostic and treatment standards.

Furthermore, Vivet Therapeutics received Fast Track designation from the FDA for its gene therapy candidate VTX-801, reflecting growing momentum toward innovative and potentially curative treatments for Wilson’s Disease.

 

To Know in detail about the Wilson’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Wilson’s Disease Market Forecast

Some of the key highlights from the Wilson's Disease Market Insights Report:

• The Wilson’s Disease market size in the 7MM was approximately USD 295 million in 2023.
• Several key pharmaceutical companies, including Orphalan, AstraZeneca, Vivet Therapeutics, Pfizer,Ultragenyx Pharmaceutical, and others, are developing novel products to improve the Wilson's Disease treatment outlook.
• In January 2026, Hyloris Pharmaceuticals obtained exclusive license rights in Europe and Turkey from ArborMed for an investigational next-generation Wilson's Disease therapy, with first-in-human trials planned for 2026 and patient studies by 2027.
• In November 2025, Monopar Therapeutics presented Phase 2 copper balance study data (ALXN1840-WD-204) at the American Association for the Study of Liver Diseases (AASLD) annual meeting, demonstrating rapid and sustained reduction in daily copper balance through increased fecal copper excretion.
• In March, 2025, European Association for the Study of the Liver (EASL) and European Reference Network (ERN) published new Clinical Practice Guidelines on Wilson's Disease, introducing significant advancements in diagnosis, monitoring, and treatment recommendations.
• In March 2025, Eton Pharmaceuticals, Inc. announced the launch of Galzin® (zinc acetate) capsules, now available exclusively through Optime Care. Galzin is the only FDA-approved zinc therapy for Wilson disease, a rare genetic disorder causing excessive copper accumulation in the body.
• In January 2025, Eton Pharmaceuticals, Inc., announced that Galzin is an FDA-approved treatment for Wilson Disease, an ultra-rare metabolic disorder.
• According to DelveInsight's estimates, there were approximately 8,000 diagnosed prevalent cases of Wilson's disease across the 7MM in 2023. These cases are expected to rise during the forecast period (2024–2034).
• In 2023, the market for Wilson's Disease was the largest in the US within the 7MM, valued at around USD 126 million, with expectations for a 13% compound annual growth rate (CAGR) over the forecast period.
• Current treatment options primarily include Chelating agents (D-penicillamine, trientine), Zinc Salts, and others. Chelating agents accounted for the largest share of the market, reaching approximately USD 123 million in 2023 for Wilson's Disease treatment in the US.
• In May 2022, the US FDA approved Orphalan's CUVRIOR (trientine tetrahydrochloride) for treating adults with stable Wilson’s disease who are decoupled and tolerant to penicillamine.
• The Wilson's Disease treatment market in the 7MM is driven by factors such as increasing awareness, early diagnosis, advances in genetic testing, and ongoing research into new therapies. Rising prevalence, along with greater healthcare investments in rare diseases, further contributes to market growth. Additionally, patient advocacy efforts are helping to improve treatment options and expand the market.
• The US FDA has also granted Fast Track designation to VTX-801, a gene therapy from Vivet currently in clinical development for Wilson's Disease. This designation is part of the FDA’s Fast Track program, aimed at expediting the development and review of innovative treatments for serious conditions with unmet medical needs.
• As per DelveInsight analysis, the Wilson's Disease market is anticipated to witness growth at a considerable CAGR

 

Strategise your business goals by understanding market dynamics @ Wilson's Disease Market Landscape

 

Wilson's Disease Overview

Wilson’s Disease is a rare, inherited genetic disorder characterized by impaired copper metabolism, leading to toxic copper accumulation in vital organs, primarily the liver and brain. Caused by mutations in the ATP7B gene, the condition results in progressive hepatic damage, neurological symptoms, and psychiatric disturbances if left untreated. Common signs include jaundice, tremors, speech difficulties, and the presence of Kayser-Fleischer rings in the eyes. Early diagnosis through clinical evaluation, biochemical tests, and genetic analysis is crucial to prevent irreversible organ damage. Lifelong treatment, including chelating agents and zinc therapy, helps remove excess copper and maintain copper balance for improved health outcomes.

 

Do you know the treatment paradigms for different countries? Download our Wilson's Disease Treatment Market

 

Wilson's Disease Epidemiology

In 2023, there were around 37,000 prevalent cases of Wilson's Disease across the 7MM, yet the treatment market for the condition lacks therapies specifically approved for its management. According to the analysis, the United States recorded the highest number of diagnosed prevalent cases, with approximately 2,600, followed by Japan with nearly 2,200 cases. Conversely, Spain had the fewest diagnosed prevalent cases, totaling approximately 300.

 

Wilson's Disease Epidemiology Segmentation

DelveInsight’s Wilson's Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Wilson's Disease historical patient pools and forecasted Wilson's Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Wilson's Disease Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

• Wilson's Disease Prevalence
• Age-Specific Wilson's Disease Prevalence
• Gender-Specific Wilson's Disease Prevalence
• Diagnosed and Treatable Cases of Wilson's Disease

 

Visit for more @ Wilson's Disease Epidemiological Insights

 

Wilson's Disease Market Insights

The Wilson’s Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Wilson’s Disease market trends by analyzing the impact of current Wilson’s Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Wilson’s Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Wilson’s Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The Wilson's Disease market is primarily driven by increased awareness, early diagnosis, and advancements in genetic testing that enable timely intervention. A growing number of treatment options, including novel chelating agents and gene therapy research, are also accelerating market growth. Supportive regulatory frameworks and incentives for orphan drug development further boost pharmaceutical investments in Wilson's Disease therapies. Additionally, patient advocacy groups and awareness campaigns play a crucial role in improving access to treatment and driving demand for innovative solutions.

However, the Wilson's Disease market faces several barriers. The rarity of the disease often leads to misdiagnosis or delayed diagnosis, hindering timely treatment initiation. High treatment costs, especially for lifelong therapies, can limit access in low- and middle-income regions. Limited awareness among general practitioners and inadequate screening protocols also pose significant challenges. Furthermore, the small patient population makes large-scale clinical trials difficult, slowing down the development and commercialization of new therapies. Despite these barriers, continued research and improved diagnostic infrastructure offer hope for overcoming current limitations in the Wilson's Disease market.

According to DelveInsight, the Wilson’s Disease market in 7MM is expected to witness a major change in the study period 2020-2034.

• In 2023, the therapeutic market for Wilson's Disease in the 7MM was valued at approximately USD 295 million. The market is projected to grow at a CAGR of 12%, driven by increased disease awareness, improved diagnostic capabilities, and the introduction of emerging therapies.
• Among the 7MM, the United States represented the largest market share, accounting for roughly 43% of the total market in 2023. This was significantly higher compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Several new drugs are under development for Wilson’s disease, including VTX-801 by Vivet Therapeutics and UX701 by Ultragenyx Pharmaceutical. These agents aim to offer improved treatment options for this challenging condition.

 

For more information, visit Wilson's Disease Market Analysis, Patient Pool, and Emerging Therapies

 

Scope of the Wilson’s Disease Market Report

• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Wilson's Disease Drugs - CUVRIOR, CUPRIOR, VTX-801, UX701, others
• Wilson's Disease Companies - Orphalan, AstraZeneca,Vivet Therapeutics,Pfizer,Ultragenyx Pharmaceutical, and others
• Wilson’s Disease Therapeutic Assessment: Wilson’s Disease current marketed and Wilson’s Disease emerging therapies
• Wilson’s Disease Market Dynamics: Wilson’s Disease market drivers and Wilson’s Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Wilson’s Disease Unmet Needs, KOL's views, Analyst's views, Wilson’s Disease Market Access and Reimbursement

 

Wilson’s Disease Report Key Insights

1. Wilson’s Disease Patient Population

2. Wilson’s Disease Market Size and Trends

3. Key Cross Competition in the Wilson’s Disease Market

4. Wilson’s Disease Market Dynamics (Key Drivers and Barriers)

5. Wilson’s Disease Market Opportunities

6. Wilson’s Disease Therapeutic Approaches

7. Wilson’s Disease Pipeline Analysis

8. Wilson’s Disease Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Wilson’s Disease Market

 

Table of Content

1. Key Insights

2. Report Introduction

3. Wilson’s disease Market Overview at a Glance

4. Executive Summary of Wilson’s disease

5. Disease Background and Overview

6. Patient Journey

7. Epidemiology and Patient Population

8. Marketed Therapies

9. Emerging Therapies

10. Wilson’s disease: 7 Major Market Analysis

11. Market Access

12. SWOT Analysis

13. Unmet Need

14. Appendix

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Why the 4.3-inch TFT LCD Is Widely Used Across Multiple Industries

The widespread cross-industry adoption of the 4.3-inch TFT LCD display stems from its precise balance of size, performance, cost, and compatibility. It not only meets the rigid demands of professional applications but also fits the cost-performance requirements of mass-market products. This analysis is structured around three dimensions: core advantages, scenario adaptability, and technological ecosystem.

I. Golden Size: Optimal Balance Between Space and Information Density

With a diagonal length of 4.3 inches (approximately 10.9 cm), this display falls into the "golden small-screen range." It avoids the cramped display limitations of 2–3-inch screens while avoiding the increased device size and power consumption of screens larger than 5 inches.Featuring common aspect ratios of 16:9 or 5:3 and mainstream resolutions such as 480×272 and 800×480, it clearly presents 4–6 lines of critical parameters (e.g., temperature, pressure, fault codes), perfectly matching the information interaction needs of industrial control and automotive terminals. Core data can be quickly accessed without scrolling.This "sufficient but not redundant" sizing enables easy integration into space-constrained devices such as CNC machine panels, portable medical instruments, and automotive secondary displays. It is friendly to structural design and can be embedded without major modifications to product enclosures.

II. Balanced Performance: Meeting Stringent Multi-Scenario RequirementsLow Power Consumption & Long Battery Life

Compared with large-screen products, 4.3-inch TFT LCDs have lower LED backlight power consumption. Combined with dynamic refresh rate technology, power use is reduced by more than 25% compared with traditional LCDs. This makes them ideal for battery-powered portable devices (handheld detectors, IoT terminals) and 24/7 industrial control equipment, supporting over 72 hours of continuous operation on a single charge.

Strong Environmental Adaptability

Industrial-grade models typically support a wide operating temperature range of −20°C to 70°C, with rugged versions capable of withstanding extreme conditions from −40°C to 85°C. They offer brightness adjustment from 300 to 1000 cd/m², maintaining clear visibility even in outdoor strong light, high-temperature workshops, or cold-chain warehouses.Some products are certified IP67 dustproof and waterproof and feature EMI electromagnetic shielding, suitable for harsh environments such as mines and oilfields.

Reliable Display & Interaction

TFT active-matrix technology drives each pixel via an independent thin-film transistor, delivering 16.7M full-color display, a 1000:1 high contrast ratio, and 10ms fast response to reduce motion blur. This satisfies precise imaging in medical devices and ensures real-time performance for automotive rearview cameras.The display supports integrated resistive or capacitive touch, replacing traditional button panels and enabling convenient operation with gloves or wet hands in special environments.

III. Mature Technology: Lowering R&D and Application BarriersExcellent Interface Compatibility

Mainstream models support multiple interfaces including RGB, SPI, MCU, and LVDS, enabling seamless connection with popular controllers such as STM32, ESP32, and Rockchip RK3566. No additional level-shifting circuits or dedicated driver chips are required, allowing "plug-and-play" integration.Engineers can treat the display as an extension of the MCU’s peripheral registers without modifying firmware driver layers, shortening system development cycles by more than 30%. This standardized interface avoids driver adaptation difficulties and greatly reduces R&D risks for embedded devices.

Supply Chain & Cost Advantages

With a long history of application, 4.3-inch TFT LCDs benefit from mature supporting resources including driver ICs (e.g., ILI6485) and backlight modules. Mass production by manufacturers such as BOE and Tianma further reduces costs.Pricing ranges from 22 to 120 RMB per unit. Basic versions suit cost-sensitive applications such as access control systems and industrial instruments, while high-end custom models meet specialized requirements in military and aerospace fields. Its cost-performance ratio exceeds that of small or large screens with equivalent functions.

Stability & Long Product Lifecycle

Through years of technical iteration, production processes for this size are highly mature, with long service life and stable supply chains, minimizing the risk of supply disruptions. For industrial and medical equipment intended for 5–10 years of service, this reliability is more valuable than short-term performance specifications.

IV. Scenario Penetration: Full Coverage from Professional Fields to Consumer ElectronicsIndustrial Control

As the core of HMI human-machine interfaces, it is widely used in CNC machines, packaging machinery, and logistics PDAs. High contrast and wide-temperature performance ensure accurate operation in bright, vibrating workshop environments, while glove-compatible touch suits warehousing and cold-chain operations.

Automotive Electronics

Applied in rearview monitors, driving recorders, and navigation secondary screens, 178° full viewing angles (IPS technology) and fast response reduce driving blind spots. High brightness prevents overexposure in strong sunlight, and MIPI interface compatibility with automotive-grade chips ensures driving safety.

Medical Equipment

Used in portable monitors, ultrasound diagnostic devices, and rehabilitation equipment, it delivers accurate color reproduction and high resolution to clearly display ECG readings, lesion images, and other critical data. Low power extends battery life for mobile medical devices, and wide-temperature performance adapts to ICUs and field emergency care.

Smart Home & IoT

Deployed in smart control panels, video intercoms, and environmental monitoring terminals, its compact size saves installation space while supporting static brand logo display and dynamic device status updates, balancing practicality and brand visibility.

Technically, the success of the 4.3-inch TFT LCD does not rely on a single advantage but on a combined strength of size adaptability, universal performance, and ecosystem maturity, making it a cross-industry "universal interface." If you would like details on selection for specific fields (e.g., industrial control, medical equipment) or comparisons between different resolutions and interface types, please provide more scenario information, and I will outline targeted application solutions and selection recommendations.

Media Contact
Company Name: Xunrui Optoelectronics Technology Co., Ltd.
Email:Send Email
Country: China
Website: https://www.tftlcm.com/

Water Supply Infrastructure: HDPE Pipe Solutions for Municipal Projects

Why Municipal Water Projects Choose HDPE Pipe

When I first started working with municipal water authorities across Asia and Europe, I noticed a pattern: engineers who had experienced HDPE pipe systems consistently specified them again, while those who hadn't often hesitated at the initial cost. After a decade supporting infrastructure buyers through supplier qualification and equipment specification, I've seen this pattern hold true across hundreds of projects.

The core advantage is economics, not just engineering. HDPE pipe costs 20-40% more upfront than PVC or ductile iron, but municipalities save 15-30% on total lifecycle cost because HDPE doesn't corrode, doesn't scale, and practically eliminates joint failures. In a 50-year municipal infrastructure horizon, that equation always resolves in HDPE's favor.

High-density polyethylene (HDPE) pipe has become the preferred choice for municipal water supply infrastructure because it combines exceptional durability with installation flexibility. Unlike metallic pipes that corrode over decades, HDPE remains chemically inert in soil and water environments. This isn't theoretical—ASTM D3350-14 material standards guarantee consistent performance across the pipe's operational lifetime.

HDPE Pipe Specifications for Municipal Applications

Material Grades and Pressure Ratings

Municipal water systems operate at pressures typically ranging from 10 to 25 bar, depending on elevation changes and distribution network design. HDPE pipes for these applications use PE100 or PE112 resin grades, which offer:

• Minimum Required Strength (MRS): 10 MPa (PE100) or 11.2 MPa (PE112) at 20°C
• Hydrostatic Design Basis (HDB): 1,600 psi (11 MPa) per ISO 4427
• Resistance to Slow Crack Growth (ESCR): >500 hours, critical for buried applications

PN ratings matter for project specification. PN16 (16 bar rated) handles most municipal distribution needs, while PN20 or PN25 becomes necessary for high-rise water supply, pump station headers, or transmission mains with large diameter drops. Always specify the next rating above your calculated maximum operating pressure—overengineering here costs little but prevents catastrophic failure.

Standard Dimension Ratios (SDR)

The SDR (Standard Dimension Ratio) defines wall thickness relative to outer diameter. Lower SDR means thicker walls and higher pressure capacity:

SDR	Pressure Rating (PN)	Typical Application	Wall Thickness (DN315)
SDR 11	PN20	Transmission mains, pump headers	28.6 mm
SDR 13.6	PN16	Main distribution lines	23.2 mm
SDR 17	PN12.5	Branch lines, service connections	18.5 mm
SDR 21	PN10	Gravity-fed systems, irrigation	15.0 mm

Installation Standards and Best Practices

Butt Fusion Jointing: The Gold Standard

For pipes DN90 and above, butt fusion is the preferred joining method. This process heats pipe ends to 210°C using a calibrated fusion machine, then joins them under controlled pressure. The result is a joint with 100% joint efficiency—the fused connection has the same strength as the pipe itself.

When I visited a water authority project in Northern Europe last year, their maintenance crew mentioned they hadn't experienced a joint failure in 15 years of operation across 200km of installed HDPE. This aligns with industry data showing failure rates below 0.1 per 100km annually for properly fused HDPE systems.

Fusion quality is non-negotiable. Every butt fusion joint must be logged with the fusion machine's data recorder, including temperature, pressure, and cooling time. I recommend specifying IPEX or Georg Fischer equipment brands for municipal projects—they offer traceability documentation that satisfies most water authority requirements.

Electrofusion for Constrained Installations

Electrofusion fittings contain embedded heating coils that fuse when energized. While 2-3x more expensive than butt fusion per joint, electrofusion becomes essential when:

• Space constraints prevent fusion machine access
• Existing valves or services require branch connections
• Repair of damaged sections in existing pipelines
• Transition to different pipe materials

Trenchless Installation Methods

HDPE's flexibility makes it exceptionally well-suited for trenchless installation, reducing disruption to roads, railways, and existing infrastructure:

Horizontal Directional Drilling (HDD)

HDD allows installation beneath obstacles with minimal surface disturbance. HDPE's elongation at break exceeding 700% means it can be pulled through bore paths without damage. For municipal projects crossing rivers, highways, or urban areas, HDD with HDPE has become the default specification.

Pipe Bursting

When rehabilitating aging cast iron or concrete pipes, pipe bursting fractures the existing pipe while pulling in replacement HDPE. This trenchless approach costs 40-60% less than open-cut replacement in established urban areas, according to NASTT (North American Society for Trenchless Technology) data.

Cost Analysis: HDPE vs. Alternative Materials

Material selection for municipal water projects requires lifecycle cost analysis, not just unit pricing. Here's how HDPE compares over a 50-year analysis period:

Cost Factor	HDPE	Ductile Iron	PVC
Material Cost (DN315)	$8-12/m	$15-22/m	$6-9/m
Installation Cost	$18-25/m	$30-45/m	$20-30/m
Joint Failure Rate	0.1/100km/yr	2.5/100km/yr	0.8/100km/yr
Expected Service Life	50-100 years	50-75 years	25-50 years
Maintenance Cost (50yr)	$5/m	$35/m	$15/m
Total 50-Year Cost	$31-42/m	$80-102/m	$41-54/m

These numbers explain the accelerating HDPE adoption. When Bangkok's water authority ran their lifecycle cost analysis for the 2024 infrastructure expansion, HDPE saved them $2.3 billion over 30 years compared to ductile iron. The payback period on HDPE's higher upfront cost was under 4 years.

Selecting an HDPE Pipe Manufacturer

Certification Requirements

• ISO 9001:2015 quality management system certification
• ISO 4427 compliance for PE pipe systems
• ASTM D3350 material classification certificates
• Water authority approvals (WATERMARK, KIWA, NSF)
• Batch test reports from independent laboratories

Production Capability Verification

When I qualify new equipment suppliers for Extrusion Lines, I always request factory visits. For HDPE pipe production, key indicators include:

Extrusion Line Specifications

Modern HDPE pipe lines use single-Screw Extruders with barrier-type screws. Look for lines equipped with:

• Laser diameter measurement with real-time SDR adjustment
• Wall thickness gauging (beta or X-ray)
• Printers marking production date and standards compliance
• Coiling or cutoff saws

Ask for production trial footage. Any reputable manufacturer will provide video of test runs showing consistent pipe diameter, smooth inner walls, and proper fusion of coextruded layers. Consistency in the first 30 seconds of a production run tells you about the line's control systems.

Quality Assurance Documentation

1. Material Data Sheets: Confirm resin is PE100 or PE112
2. Pipe Weight Verification: Actual vs. theoretical weight
3. Hydrostatic Test Reports: Tested to 1.5x rated pressure
4. OD/ID Dimensional Logs: Statistical process control charts
5. Fusion Compatibility Certificate

Municipal Project Case Study

In 2023, I supported a water authority in Southeast Asia transitioning from ductile iron to HDPE for their main distribution network.

Metric	Target	Actual
Installation Cost (vs. DI baseline)	-15%	-22%
Leak Incidents (per 100km)	<0.5	0.2
Water Loss Reduction	12%	18%
Project Timeline	18 months	16 months

The Future of Municipal Water Infrastructure

HDPE pipe installation increasingly integrates with smart water network monitoring. Acoustic sensors can be embedded during installation to detect leak signatures, while pre-installed telemetry ports enable real-time pressure and flow monitoring.

Media Contact
Company Name: Shanghai Jurry Plastics Machinery Co., Ltd.
Email:Send Email
Country: China
Website: https://www.jurryextrusion.com/

Flip Range Hood Drive System VS Lifting Range Hood Drive System

With the rapid development of the smart home industry, kitchen and bathroom appliances are becoming increasingly intelligent. Nowadays, many home decoration styles tend to integrate the kitchen with the living room. Open kitchens are widely popular for their sense of space and interactivity. However, this design also brings new challenges—cooking fumes can easily spread around, not only affecting indoor air quality but also interfering with the aesthetics of open spaces. Meanwhile, consumer demands for kitchen appliances are becoming more diversified. They are not only pursuing efficiency and convenience but also expect kitchen appliances to better integrate into the smart home ecosystem.

The smart range hood has emerged to meet these needs. It is a high-tech household appliance that integrates microprocessors, sensor technology, and network communication technology. With the help of modern industrial automatic control technology, Internet technology, and multimedia technology, the smart range hood can automatically identify the working environment and its own status, achieving intelligent control. Users can easily operate the range hood through local actions or remote commands, enjoying a more convenient user experience. As part of the smart home ecosystem, the smart range hood can also interconnect with other home appliances and facilities, forming a collaborative smart system that creates a more intelligent and humanized home environment.

Sinbad Motor offers a more convenient user experience. Its main features include:

- Planetary Gearbox Design: It adopts a planetary gearbox structure, which provides good noise reduction performance. The quiet operation enhances the comfort of the kitchen environment.- Efficient Transmission Combination: By combining a planetary gearbox with worm gear transmission, it achieves smooth and easy panel flipping, making the operation more fluid.

Media Contact
Company Name: Dongguan Sinbad Motor Co., Ltd.
Email:Send Email
Country: China
Website: https://www.sinbadmotor.com/

Hypoglycemia Clinical Trials Surge as 15+ Companies Advance 20+ Therapies across Multiple Development Stages, analyses DelveInsight

Hypoglycemia Clinical Trials

As per DelveInsight’s assessment, globally, Hypoglycemia pipeline constitutes 15+ key companies continuously working towards developing 20+ Hypoglycemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Hypoglycemia Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypoglycemia Market.

The Hypoglycemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Get a Free Sample PDF Report to know more about Hypoglycemia Pipeline Therapeutic Assessment - https://www.delveinsight.com/report-store/hypoglycemia-pipeline-insight

 

Some of the key takeaways from the Hypoglycemia Pipeline Report:

• Hypoglycemia companies across the globe are diligently working toward developing novel Hypoglycemia treatment therapies with a considerable amount of success over the years.
• Hypoglycemia companies working in the treatment market are Twist Bioscience, MBX Biosciences, Eiger BioPharmaceuticals, Hanmi Pharmaceutical, Zealand Pharma, Vogenx, Inc., RECORDATI GROUP, Zucara Therapeutics, Vertex Pharmaceutical, Hanmi Pharmaceutical, and others, are developing therapies for the Hypoglycemia treatment

• Emerging Hypoglycemia therapies in the different phases of clinical trials are- Zimislecel, Imapextide, ZT-01, Avexitide, OPF-310, CRG-002, CFTX-2034, Mizagliflozin, Pasireotide Diaspartate, Retatrutide, and others are expected to have a significant impact on the Hypoglycemia market in the coming years.
• In March 2026, Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that the last participant has been randomized and dosed in the pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation in post-bariatric hypoglycemia (PBH). LUCIDITY is a 16-week, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of avexitide in adults with PBH following Roux-en-Y gastric bypass (RYGB) surgery. Participants who complete the 16-week double-blind period are eligible to enter a 32-week open-label extension period. The trial has enrolled 78 participants, with topline data readout anticipated in Q3 2026. If approved, commercial launch of avexitide is anticipated in 2027.
• In December 2024, Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) has unveiled the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational first-in-class GLP-1 receptor antagonist aimed at treating post-bariatric hypoglycemia (PBH). The trial will assess the FDA-agreed primary outcome of reducing hypoglycemia events and will maintain similar inclusion and exclusion criteria as previous Phase 2 studies of avexitide in PBH. Amylyx plans to begin dosing the first participant in early 2025, complete recruitment within the same year, and release topline results in 2026.
• In November 2024, MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced the completion of the final subject’s last visit in its Phase 1 trial of MBX 1416. This study, which evaluated single and multiple ascending doses, focuses on MBX 1416, a long-acting GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia (PBH).

 

Hypoglycemia Overview

Hypoglycemia is a condition characterized by an abnormally low level of glucose (sugar) in the blood. Glucose is the primary energy source for the body's cells, especially the brain, and maintaining normal blood glucose levels is essential for proper bodily function.

 

Explore the latest Hypoglycemia pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Hypoglycemia Clinical Trials

 

Emerging Hypoglycemia Drugs Under Different Phases of Clinical Development Include:

• TB 222 023: Twist Bioscience
• MBX 1416: MBX Biosciences
• Avexitide: Eiger BioPharmaceuticals
• HM 15136: Hanmi Pharmaceutical
• Dasiglucagon: Zealand Pharma
• Mizagliflozin: Vogenx, Inc.
• Pasireotide Diaspartate: RECORDATI GROUP
• ZT-01: Zucara Therapeutics
• VX-880: Vertex Pharmaceutical
• HM15136: Hanmi Pharmaceutical

 

Hypoglycemia Pipeline Outlook

Zimislecel: Vertex Pharmaceuticals Incorporated

Zimislecel (previously known as VX-880) is an allogeneic, stem cell-derived therapy composed of fully differentiated insulin-producing islet cells, developed using proprietary technology. It is intended for individuals with Type 1 Diabetes (T1D) who experience impaired awareness of hypoglycemia along with severe episodes. The therapy is administered via infusion into the hepatic portal vein and requires immunosuppressive treatment to prevent rejection of the transplanted islet cells. Currently, Zimislecel is in Phase III clinical development for the treatment of hypoglycemia.

 

Imapextide: MBX Biosciences

Imapextide (MBX 1416) is an investigational, long-acting GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia (PBH). The therapy works by blocking excessive GLP-1 secretion after meals, which is known to trigger hyperinsulinemia and subsequently lead to hypoglycemia. By reducing GLP-1-driven insulin spikes, Imapextide aims to regulate insulin levels, increase blood glucose, and minimize both the frequency and severity of hypoglycemic events. It is designed for convenient once-weekly dosing and is currently in Phase II clinical trials.

 

ZT-01: Zucara Therapeutics

ZT-01, developed by Zucara Therapeutics, is a first-in-class, once-daily therapy designed to prevent insulin-induced hypoglycemia in patients undergoing insulin treatment. The drug functions by inhibiting somatostatin, a hormone that suppresses glucagon release during hypoglycemic episodes in individuals with insulin-dependent diabetes. By restoring the body’s natural glucagon response, ZT-01 aims to prevent hypoglycemia and significantly improve disease management as well as patient quality of life. The therapy is currently in Phase II clinical development.

 

Hypoglycemia Route of Administration

Hypoglycemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

 

Hypoglycemia Molecule Type

Hypoglycemia Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Hypoglycemia Pipeline Therapeutics Assessment

• Hypoglycemia Assessment by Product Type
• Hypoglycemia By Stage and Product Type
• Hypoglycemia Assessment by Route of Administration
• Hypoglycemia By Stage and Route of Administration
• Hypoglycemia Assessment by Molecule Type
• Hypoglycemia by Stage and Molecule Type

 

DelveInsight's Hypoglycemia Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Further Hypoglycemia product details are provided in the report. Download the Hypoglycemia pipeline report to learn more about the emerging Hypoglycemia therapies

 

Some of the key companies in the Hypoglycemia Therapeutics Market include:

Key companies developing therapies for Hypoglycemia are - Amphastar Pharmaceuticals, Eiger BioPharmaceuticals, Eli Lilly, Novo Nordisk, Xeris Pharmaceuticals, Fresenius Kabi, Zeal and Pharma, and others.

 

Hypoglycemia Pipeline Analysis:

The Hypoglycemia pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hypoglycemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypoglycemia Treatment.
• Hypoglycemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypoglycemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypoglycemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Hypoglycemia drugs and therapies

 

Hypoglycemia Pipeline Market Drivers

• Rising prevalence of Hypoglycemia, Rising awareness, are some of the important factors that are fueling the Hypoglycemia Market.

 

Hypoglycemia Pipeline Market Barriers

• However, High cost of clinical trial research, increasing side effects associated with treatment and other factors are creating obstacles in the Hypoglycemia Market growth.

 

Scope of Hypoglycemia Pipeline Drug Insight

• Coverage: Global
• Key Hypoglycemia Companies: Twist Bioscience, MBX Biosciences, Eiger BioPharmaceuticals, Hanmi Pharmaceutical, Zealand Pharma, Vogenx, Inc., RECORDATI GROUP, Zucara Therapeutics, Vertex Pharmaceutical, Hanmi Pharmaceutical, and others
• Key Hypoglycemia Therapies: TB 222 023, MBX 1416, Avexitide, HM 15136, Dasiglucagon, Mizagliflozin, Pasireotide Diaspartate, ZT-01, VX-880, HM15136, and others
• Hypoglycemia Therapeutic Assessment: Hypoglycemia current marketed and Hypoglycemia emerging therapies
• Hypoglycemia Market Dynamics: Hypoglycemia market drivers and Hypoglycemia market barriers

 

Request for Sample PDF Report for Hypoglycemia Pipeline Assessment and clinical trials

 

Table of Contents

1. Hypoglycemia Report Introduction

2. Hypoglycemia Executive Summary

3. Hypoglycemia Overview

4. Hypoglycemia- Analytical Perspective In-depth Commercial Assessment

5. Hypoglycemia Pipeline Therapeutics

6. Hypoglycemia Late Stage Products (Phase II/III)

7. Hypoglycemia Mid Stage Products (Phase II)

8. Hypoglycemia Early Stage Products (Phase I)

9. Hypoglycemia Preclinical Stage Products

10. Hypoglycemia Therapeutics Assessment

11. Hypoglycemia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hypoglycemia Key Companies

14. Hypoglycemia Key Products

15. Hypoglycemia Unmet Needs

16 . Hypoglycemia Market Drivers and Barriers

17. Hypoglycemia Future Perspectives and Conclusion

18. Hypoglycemia Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Bread Loaf's CEO Mark Milutin Breaks Down FDA Peptide Shift and What It Means for Telehealth

"This is telehealth's 2012 e-commerce moment. Regulation, consumer demand, and technology are aligning at the same time — and the operators who move first aren't just going to win, they're going to define the category." — Mark Milutin, Founder, Bread Loaf

Direct response agency Bread Loaf and founder Mark Militant released an emergency episode of The Brand Building Podcast today, analyzing the FDA's decision to move 12 peptides out of Category 2 and what the regulatory shift means for telehealth marketing, LegitScript certification, and growth.

Newport Beach, CA - April 17, 2026 - Bread Loaf, the direct response agency specializing in growth and retention for telehealth and e-commerce brands, today released an emergency episode of The Brand Building Podcast analyzing a major FDA policy shift announced earlier in the day. Founder and host Mark Milutin breaks down what the decision to move 12 peptides out of Category 2 means for telehealth operators, marketers, and the broader longevity category.

The announcement, made by Health and Human Services Secretary Robert F. Kennedy Jr., signals that the FDA will pull 12 peptides — including BPC-157, Epitalon, GHK-Cu, MOTS-c, Semax, Melanotan II, Thymosin beta-4 fragment, DSIP, Dihexa Acetate, Ibutamoren Mesylate, KPV, and Cathelicidin LL-37 — from the Category 2 "Bulk Drug Substances that Raise Significant Safety Risks" list. The peptides will instead be brought to the Pharmacy Compounding Advisory Committee (PCAC) for formal scientific review beginning in July 2026.

In the episode, titled "Peptides Just Got a Green Light — Here's What It Means for Telehealth Marketing," Milutin argues the regulatory move is the most significant unlock the telehealth category has seen in years.

"For the past couple of years, a lot of these compounds were pushed into a gray zone that didn't eliminate demand — it just pushed it underground," said Milutin. "This shift from restriction to review changes how consumers, providers, and even payment platforms see the category. When regulation signals these compounds are worth studying on their merits, confidence flips like a switch."

The episode, available now on The Brand Building Podcast, covers the operational implications for telehealth brands, including:

The opening of LegitScript certification pathways for peptide protocols, which will directly impact the ability to run paid media on Meta and Google. The loosening of restrictions from email service providers (ESPs) and payment processors that have historically declined to work with peptide-adjacent telehealth brands. The expected explosion in supply-side competition as clinics, compounding pharmacies, and telehealth operators expand their SKUs. The shift in consumer confidence as social proof, influencer adoption, and media narratives normalize peptides as part of the longevity and optimization conversation.

Milutin also highlights the retention opportunity unique to the category: "Peptides are a repeat-purchase, subscription-native behavior. The winners won't just run good acquisition — they'll win on lifecycle, onboarding education, dosage reminders, and progress tracking. That's where the LTV gets built."

The emergency episode follows a podcast released earlier the same day on why telehealth brands are getting kicked off Klaviyo and other non-HIPAA-compliant email service providers — a one-two release that positions Bread Loaf at the center of both the regulatory and operational conversations shaping the category.

Bread Loaf works with telehealth brands across paid media, retention, and lifecycle marketing, building growth infrastructure designed to scale in regulated, compliance-sensitive categories. Milutin believes the current moment mirrors the early days of e-commerce.

"This feels like e-commerce in 2012 — with 2026 tools," said Milutin. "Traditional healthcare is going to be blindsided. The savage operators who understand paid media, retention, and brand building are the ones who are going to define this category."

The full episode of The Brand Building Podcast is available now on all major podcast platforms.

About Bread Loaf

Bread Loaf is a direct response growth marketing / AD agency specializing in growth and retention for telehealth, e-commerce, and healthcare brands. Led by founder Mark Milutin, Bread Loaf builds paid media and lifecycle marketing systems designed for the compliance-sensitive realities of modern regulated categories, helping brands scale to millions of dollars per month through a combination of traffic arbitrage, customer experience, and retention infrastructure.

About The Brand Building Podcast

The Brand Building Podcast, hosted by Bread Loaf founder Mark Milutin, covers growth, retention, and brand strategy for operators building in e-commerce, telehealth, and emerging regulated categories. New episodes release regularly across all major podcast platforms.

Media Contact
Company Name: Brand Building Podcast
Contact Person: Mark Milutin
Email:Send Email
City: Newport Beach
State: CA
Country: United States
Website: https://www.brandbuildingpodcast.com/

CoreAge Rx Highlights Strong Patient Satisfaction Through Trustpilot Reviews, BBB Presence, and Independent Recognition Across Telehealth Platforms

Positive patient experiences, structured care delivery, and speed-driven fulfillment reinforce CoreAge Rx’s growing reputation in weight management telehealth.

CoreAge Rx, a LegitScript-certified telehealth weight management provider based in Wichita Falls, Texas, continues to strengthen its position in the digital healthcare space through consistently positive patient feedback, structured clinical processes, and a delivery model designed for speed, reliability, and patient convenience.

Trustpilot Reviews Reflect Strong Patient Experience

Independent feedback on Trustpilot highlights overwhelmingly positive experiences among patients using the CoreAge Rx platform. Reviewers frequently point to the effectiveness of the program, noting meaningful progress in weight management, including reduced cravings and fewer obsessive food-related thoughts.

Patients consistently describe the overall experience as streamlined and efficient, from the initial onboarding process to ongoing refills. The platform’s usability is often characterized as easy, thorough, and quick, allowing individuals to navigate their treatment journey without unnecessary complexity.

Delivery performance is another frequently praised aspect. Many reviewers highlight fast and discreet shipping, with medications often arriving within just a few days. This efficiency plays a critical role in maintaining continuity in physician-directed care plans.

Customer support also receives notable recognition, with many patients appreciating prompt and helpful responses to their questions. At the same time, some feedback points to occasional delays in shipping timelines, limited tracking visibility, and instances where support responses were perceived as vague or slower than expected. These insights reflect a balanced review landscape, offering transparency into both strengths and areas for continued refinement.

BBB Profile Reinforces Transparency and Accountability

In addition to patient reviews, CoreAge Rx maintains an active presence on the Better Business Bureau (BBB), where its profile reflects a commitment to transparency and structured customer service practices.

Patients often view BBB listings as a benchmark for trustworthiness, particularly within telehealth and weight management services. CoreAge Rx’s profile highlights its responsiveness to customer inquiries and its organized approach to resolving concerns; two critical factors for individuals navigating remote healthcare solutions.

By actively engaging with feedback and maintaining accountability through its BBB profile, CoreAge Rx reinforces its position as a patient-focused provider that prioritizes ongoing support and clear communication throughout the treatment journey.

Independent Platforms Further Validate Patient Satisfaction

Beyond direct patient feedback, CoreAge Rx has received strong recognition from multiple independent review platforms, further supporting its growing reputation.

A featured evaluation published by Healthy Pound awarded CoreAge Rx a 4.5 out of 5 rating, highlighting its physician-supervised care model, structured eligibility process, and direct-to-door delivery system. The review emphasized the clarity of its clinical pathway and the role of board-certified physicians in guiding treatment decisions.

American Made GLP-1 also recognized CoreAge Rx as the best GLP-1 provider for 2026 following its evaluation of the platform’s physician oversight, accessible pricing, and use of compounded medications prepared under regulated quality standards.

Further reinforcing this position, Compare GLP-1 Medication ranked CoreAge Rx as the number one provider on its platform, supported by more than 12,800 verified patient reviews and an overall rating of 4.9 out of 5. Reported patient outcomes included measurable progress in weight management, with reviewers consistently highlighting ongoing physician involvement and structured support as key differentiators.

Speed-Driven Care Model Enhances Patient Experience

CoreAge Rx has designed its operational model around speed as a central component of care delivery. From the moment a patient begins their journey, each step is optimized to reduce delays and maintain treatment continuity.

Patients start with a secure online health assessment, which is reviewed by board-certified physicians within approximately 24 hours. In many cases, qualifying individuals receive same-day prescription approvals. This accelerated clinical review significantly shortens the time between initial consultation and treatment initiation.

Once approved, prescriptions move directly into fulfillment, eliminating administrative bottlenecks that commonly slow down traditional healthcare workflows. This integrated approach ensures that patients can begin their physician-directed programs without unnecessary waiting periods.

For individuals participating in metabolic care programs, compounded Semaglutide and Tirzepatide require careful handling and timely delivery. CoreAge Rx aligns its operational speed with strict handling protocols, ensuring that medication integrity is preserved throughout the process.

Fast, Reliable Shipping and Patient-Centered Fulfillment

CoreAge Rx integrates shipping as a core extension of patient care rather than a secondary service. Every prescription includes free two-day delivery, applied universally without additional fees or conditions. This ensures that patients receive their medication quickly, supporting adherence to physician-directed care plans.

All medications are shipped using temperature-controlled packaging designed to maintain consistent conditions throughout transit. This cold-chain handling process ensures that compounded medications arrive in optimal condition, preserving their intended quality and effectiveness.

Discretion is another key element of the delivery experience. Shipments arrive in plain, unbranded packaging, protecting patient privacy and aligning with the platform’s fully confidential care model.

The speed of delivery is further supported by rapid prescription processing. With physician reviews completed within approximately 24 hours, and often on the same day, medications move quickly from approval to shipment, reducing the total time patients spend waiting to begin treatment.

The entire process is structured to remove friction at every stage. Patients complete an online assessment, receive physician evaluation, and have their medication delivered directly to their door without the need for in-person visits, pharmacy pickups, or complex administrative procedures.

Customer Support Strengthens Overall Experience

While operational speed is a defining feature of the CoreAge Rx model, the company complements this with a strong emphasis on customer support. Patients have access to assistance throughout their journey, helping them navigate questions, concerns, and ongoing care needs.

This combination of responsiveness, structured processes, and reliable fulfillment contributes to a consistent patient experience; one that is reflected across both direct reviews and independent evaluations.

A Growing Standard in Telehealth

As telehealth continues to evolve, platforms that successfully combine clinical oversight, operational efficiency, and patient-centered design are shaping the future of healthcare delivery.

CoreAge Rx exemplifies this shift through its speed-driven infrastructure, structured care model, and strong patient feedback across platforms such as Trustpilot and BBB. By aligning clinical processes with fast, reliable fulfillment and ongoing support, the company continues to enhance access, consistency, and confidence in modern weight management care.

About CoreAge Rx

CoreAge Rx is a LegitScript-certified telehealth weight management provider based in Wichita Falls, Texas. The company connects eligible adults across the United States with board-certified physicians who evaluate patients through a secure online health assessment and oversee personalized treatment plans.

Operating through a fully digital platform, CoreAge Rx eliminates the need for in-person visits, traditional pharmacy pickups, and complex administrative processes. The program is designed to provide a streamlined, end-to-end experience; from consultation and physician review to prescription fulfillment and direct-to-door delivery.

CoreAge Rx offers compounded Semaglutide starting at $99 per month and compounded Tirzepatide starting at $149 per month, with flat-rate pricing across all dose levels. Every prescription includes free two-day shipping, temperature-controlled packaging, and discreet delivery to ensure both convenience and privacy.

With a focus on structured clinical oversight, fast processing timelines, and responsive customer support, CoreAge Rx continues to build a patient-centered model that prioritizes accessibility, continuity of care, and a consistent treatment experience in the evolving telehealth landscape.

For more information, visit www.coreagerx.com.

Inquiries can be sent to support@coreagerx.com or called at +1 940-400-4927.

Media Contact
Company Name: CoreAge Rx
Contact Person: Ella Jones
Email:Send Email
Phone: +1 940-400-4927
City: Wichita Falls
State: TX
Country: United States
Website: www.coreagerx.com

How to Choose the Right Digital Agency in Cape Town for Long-Term Growth

Finding the right digital agency is one of the most important decisions a business can make. In a market like Cape Town, where competition is increasing across nearly every industry, the difference between average and exceptional marketing often comes down to who is managing your strategy.

Yet many businesses still approach agency selection based on price or surface-level promises, rather than long-term performance.

Understanding what actually differentiates a high-performing digital agency in Cape Town can help avoid costly misalignment and drive sustainable growth.

Not All Agencies Are Built the Same

The term digital agency has become broad to the point of being almost meaningless. It can refer to anything from freelance operators to full-service firms offering strategy, creative, paid media, and analytics.

This is why clarity matters.

A strong digital agency should not only execute campaigns but also connect marketing activity directly to business outcomes. Without that link, even well-designed campaigns can fail to deliver measurable impact.

Strategy Before Execution

One of the biggest mistakes businesses make is jumping straight into execution - launching ads, building websites, or running social campaigns - without a clear strategic foundation.

An effective marketing agency starts with:

• Clear business objectives
• Defined target audiences
• Channel prioritisation
• Measurable KPIs

Without this, marketing becomes reactive rather than intentional.

Working with an experienced marketing agency in Cape Town ensures that execution is guided by a clear strategy, not guesswork.

The Difference Between an Ad Agency and a Growth Partner

Traditionally, an ad agency focused on creative campaigns and media placement. While this still plays a role, modern businesses need more than just advertising.

Today’s leading ad agencies in Cape Town are evolving into growth partners - combining creative, data, and performance marketing into a unified approach.

This includes:

• Paid media strategy and optimisation
• Conversion tracking and analytics
• Content and creative aligned to performance
• Continuous testing and iteration

Businesses that treat their agency as a partner, rather than a supplier, tend to see significantly stronger results over time.

What to Look for in an Agency Partner

Choosing the right agency is less about who has the best pitch and more about who can consistently deliver results.

Key factors to evaluate include:

• Proven track record across industries
• Clear reporting and transparency
• Ability to tie activity to revenue or leads
• Strategic thinking, not just execution
• Strong communication and accountability

A credible ad agency should be able to clearly explain how their work contributes to your business objectives - not just marketing metrics.

Why Local Market Understanding Matters

Cape Town has a unique business environment. Consumer behaviour, competition levels, and channel effectiveness can differ significantly from other regions.

Working with a local agency provides:

• Better understanding of the target market
• More relevant messaging and positioning
• Faster alignment and communication
• Stronger network and local insight

This is particularly important for businesses competing in saturated or highly competitive industries.

The Shift Toward Performance-Driven Marketing

Marketing is becoming increasingly measurable. Businesses expect clear returns on their investment, and agencies are under pressure to deliver results that can be tracked and validated.

This has led to a shift toward:

• Data-driven decision making
• Continuous optimisation
• Integration between channels
• Focus on ROI rather than activity

A modern digital agency is not judged by how much work they produce, but by the outcomes they generate.

Author Bio

Brandright is a Cape Town-based digital and marketing agency focused on delivering performance-driven strategies that align marketing activity with real business outcomes.Learn more about their approach at Brandright.

Media Contact
Company Name: Brandright
Contact Person: Andrew
Email:Send Email
Country: South Africa
Website: https://brandright.co.za

A Voice for the Seeking Soul: Priest and Author David Beresford Brings Three Beloved Books to Readers Worldwide

Priest and author David Beresford brings his three spiritually enriching books—Blessed by God, Call to Love, and Above & Below—to readers worldwide. Now available on Amazon, Barnes & Noble, and other leading booksellers, these works invite readers into deeper faith, reflection, and contemplative living. Beresford’s writing speaks to believers, seekers, and anyone longing for a closer walk with God.

For the first time, Blessed by God, Call to Love, and Above & Below are available on Amazon, Barnes & Noble, and booksellers worldwide, an invitation for all who hunger for a deeper life with God.

There are books that inform, and then there are books that transform. Books that do not simply sit on a shelf but rest in the heart, returning to you in quiet moments, in morning prayer, in the hush between one breath and the next. The three books of David Beresford belong to that rare second kind.

David Beresford is a priest ordained in the Church of England who has spent his ministry listening: to Scripture, to tradition, to the still small voice, and to the people in his care. Since 2015, he has served as interim rector in churches across Pennsylvania and Delaware, bringing with him the spiritual richness of Anglican contemplative life. He is an Associate of CSWG, an Anglican monastic order, and contributes to Living Church Magazine and The Anglican Digest. He writes a weekly blog at http://davidberesfordwrites.com/. He is married to Ruth and makes his home in Wilmington, Delaware.

Shaped by decades of priestly ministry on both sides of the Atlantic, Beresford writes as a pastor, a poet, and a pilgrim. His words carry the weight of a man who has walked closely with God and with people, in parishes across Pennsylvania and Delaware, in the pages of Living Church Magazine and The Anglican Digest, and in a weekly blog that has quietly nurtured souls around the world.

Now, for the very first time, all three of his books are available to purchase worldwide, now on Amazon, Barnes & Noble, and leading booksellers across the globe. Whether you are a lifelong believer, someone returning to faith after a long absence, or a soul simply asking Is God there? Does He speak? How do I listen? These books were written for you.

Three Books. One Journey. An Invitation to Draw Near.

Blessed by God

What does it mean to be blessed? Not in the shallow sense of good fortune, but in the profound, biblical sense, touched by God, known by God, held by God. In his most recent work, Beresford opens the Scriptures and the landscape of everyday life to reveal blessing woven into places we might never have thought to look: in loss and in beauty, in silence and in noise, in the ordinary and the sacred alike.

Call to Love

At the very heart of the Christian life lies a single, inexhaustible call: to love. But love, as Beresford reminds us, is not a feeling to be waited for, it is a direction to be turned toward, again and again, in prayer, in sacrifice, in the small acts of daily faithfulness. Call to Love is a warm, searching guide for all who want to respond to God’s invitation with the whole of their lives.

Above & Below

Heaven is not only above us, but it also presses in from every side, alive in the texture of creation, in poetry and in silence, in the face of a stranger and the turn of a season. Beresford’s debut collection of meditations is a masterwork of contemplative attention, teaching the reader to see the world with the eyes of faith, to find the eternal shining through the temporal, and God speaking in the places we had nearly forgotten to look.

“This beautiful book of meditations locates the eternal truths of faith in the context of living and life. Deeply thoughtful with rich connections to literature and poetry, these meditations bring the reader closer to God, closer to nature, and closer to a fuller awareness of ourselves and our faith. Read it and allow yourself to be touched by the animating Spirit that pulsates through the text. This is a book that can be read and re-read.” — The Very Reverend Ian S. Markham, Ph.D.

Dean, President & Professor of Theology and Ethics, Virginia Theological Seminary

A Word to the Reader

Perhaps you have found yourself asking, in the quiet of the night or the noise of the day: How does God speak to me? How does He call me? What are the signs of the Holy Spirit in my life? Why should I go to church? How do I begin to find faith?

These are not small questions. They are the questions that matter most. And David Beresford does not answer them with easy formulas or hollow reassurances. He answers them the way a wise friend would, with honesty, with depth, with the confidence of a man who has sat with God through joy and through sorrow and found Him faithful.

Blessed by God: https://davidberesfordwrites.com/books/blessed-by-god/

Call to Love: https://davidberesfordwrites.com/books/call-to-love/

Above & Below: https://davidberesfordwrites.com/books/above-below/

All titles are available on Amazon, Barnes & Noble, and other leading booksellers worldwide.

Media Contact
Company Name: Brooks Craft Publishing
Contact Person: Darek D'Souza
Email:Send Email
Phone: +12132246630
Address:1 Seneca St
City: Buffalo
State: New York
Country: United States
Website: https://brookscraftpublishing.com/